Spectranetics receives FDA approval for advanced GlideLight laser sheath


Spectranetics has announced FDA approval of the new advanced GlideLight laser sheath for removal of cardiac leads.

Spectranetics’ current laser sheath, the SLS II, requires significantly less force to advance than mechanical telescoping sheaths. GlideLight is a major leap forward, requiring 55% less force to advance than SLS II.

“Mechanical force is a leading cause of complications during lead extraction,” said Bruce Wilkoff, director of Cardiac Pacing and Tachyarrhythmia Devices at Cleveland Clinic, USA. “Reduced force improves the control for safely removing leads. It is particularly important to have control when breaking up tough binding sites.” Wilkoff is a non-paid member of Spectranetics’ Medical Advisory Board.

“GlideLight has taken us to the next level in lead extraction,” said Charles Kennergren, professor at Sahlgrenska University Hospital, Gothenburg, Sweden, and first physician worldwide to use GlideLight clinically. “I am very impressed with the reduced force and increased control and efficiency that GlideLight has provided me.”

GlideLight will be exhibited at the Heart Rhythm Society meeting (9–11 May, Boston, USA).